Hypoxia-inducible factor stabilizers: 27 228 patients studied, yet a role still undefined

With the emergence of hypoxia inducible factor–prolyl hydroxylase inhibitors (HIF-PHIs) came the hope that using these oral drugs could improve the treatment of the anemia of kidney disease. In this editorial we discuss the accumulated knowledge on these agents and the clinical context for use.

Detalles Bibliográficos
Autores principales: Fishbane, Steven, Malieckal, Deepa A, Ng, Ji H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Editorial Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157762/
https://www.ncbi.nlm.nih.gov/pubmed/37151410
http://dx.doi.org/10.1093/ckj/sfad026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157762/
https://www.ncbi.nlm.nih.gov/pubmed/37151410
http://dx.doi.org/10.1093/ckj/sfad026

Ejemplares similares